Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||28 Jul 2021||Lorem|
|Zogenix’s fenfluramine uptake inertia expected in Dravet syndrome with entrenched competitor, though differentiated MOA provides some edge, experts say||24 Jan 2020||Shuan Sim|
|UCB to conduct bridging study of UCB0107 in progressive supranuclear palsy this year, exec says||26 Sep 2019||Shuan Sim|
|Engage Therapeutics will welcome CRO approaches for Phase III epilepsy trial in 1H20; early 2020 topline data to open doors for partnering talks, CEO says||12 Jul 2019||Shuan Sim|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward